Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of pancreatic cancer for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations, covering 171 countries and…

Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…

Pancreatic cancer is a difficult-to-treat malignancy, with dismal survival outcomes. First-line treatment of metastatic disease is limited to chemotherapy-based regimens such as FOLFIRINOX and…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…